Results from 3 studies evaluating the interaction between Addyi (flibanserin; Sprout), a treatment for hypoactive sexual desire disorder in premenopausal women, and alcohol have been submitted to the FDA for review for inclusion in the product labeling.
Risk increases associated with hormone therapy exposure over 10 years in women <60 years at initiation
Higher mindfulness and lower stress are independently associated with lower menopausal symptom scores among midlife women.
The Women’s Health Initiative (WHI) recommendations for menopausal hormone therapy (MHT) use issued in 2002 have been widely adopted, according to a study published online December 21 in Menopause.
Oral hormone replacement therapy (HRT) is associated with an increased risk for venous thromboembolism (VTE), while transdermal preparations are not linked to increased risk.
For postmenopausal women, vaginal estrogen use is not associated with negative health outcomes.
ostmenopausal women with edentulism are at an increased risk for developing hypertension, according to a study published online December 4 in the American Journal of Hypertension.
Oxybutynin, an anticholinergic used to treat urinary incontinence, may provide breast cancer survivors with an alternative treatment option for hot flashes, according to new research.
To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women’s Health Initiative (WHI) hormone therapy trials.
Approval from the Food and Drug Administration (FDA) was supported by the Phase 3 Replenish trial which evaluated the safety and efficacy of Bijuva in generally healthy, postmenopausal women with a uterus for the treatment of moderate to severe hot flashes.
